| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.26018 |
| P8608 | Fatcat ID | release_e2i6bayaoncujninfqmns3waji |
| P698 | PubMed publication ID | 22911624 |
| P2093 | author name string | Akira Honda | |
| Tadashi Ikegami | |||
| Teruo Miyazaki | |||
| Yasushi Matsuzaki | |||
| Makoto Nakamuta | |||
| Yoshifumi Saito | |||
| Hajime Takikawa | |||
| Junichi Iwamoto | |||
| Michio Imawari | |||
| Takeshi Hirayama | |||
| P2860 | cites work | The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity | Q24630723 |
| The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux | Q28186424 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Effects of long-term rifampicin administration in primary biliary cirrhosis | Q28319860 | ||
| The PPARs: from orphan receptors to drug discovery | Q28371618 | ||
| A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. | Q33891043 | ||
| The PXR is a drug target for chronic inflammatory liver disease | Q34118368 | ||
| Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. | Q34195592 | ||
| Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism | Q34405631 | ||
| 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans | Q34580565 | ||
| An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. | Q34732527 | ||
| Benefit of farnesoid X receptor inhibition in obstructive cholestasis | Q34983994 | ||
| Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. | Q35594405 | ||
| Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide | Q35826433 | ||
| Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review | Q36714163 | ||
| The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression | Q37356791 | ||
| Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC-ESI-MS/MS. | Q37715052 | ||
| A Retrospective on Nuclear Receptor Regulation of Inflammation: Lessons from GR and PPARs | Q37937451 | ||
| Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis | Q38333581 | ||
| Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice | Q38343998 | ||
| PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide | Q39896398 | ||
| Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor | Q40309271 | ||
| Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. | Q40358831 | ||
| Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor | Q40768989 | ||
| Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. | Q42483557 | ||
| Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice | Q42526889 | ||
| Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone | Q43086793 | ||
| Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. | Q43205429 | ||
| Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population | Q43585851 | ||
| Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression | Q43794445 | ||
| CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes | Q44028568 | ||
| Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle | Q44514694 | ||
| Significance of plasma 7alpha-hydroxy-4-cholesten-3-one and 27-hydroxycholesterol concentrations as markers for hepatic bile acid synthesis in cholesterol-fed rabbits | Q44697570 | ||
| Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients | Q44699692 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Q46614923 | ||
| High sensitive analysis of rat serum bile acids by liquid chromatography/electrospray ionization tandem mass spectrometry | Q46768634 | ||
| Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment | Q50174946 | ||
| Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. | Q50790143 | ||
| Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. | Q51485180 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | Q73401694 | ||
| Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis | Q77225890 | ||
| Primary biliary cirrhosis | Q81246142 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 1931-1941 | |
| P577 | publication date | 2013-04-05 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid | |
| P478 | volume | 57 |
| Q53813239 | A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. |
| Q53591523 | A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. |
| Q36116022 | Advances in pharmacotherapy for primary biliary cirrhosis |
| Q88599326 | Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness |
| Q91431676 | Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis |
| Q85345310 | Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA |
| Q33709930 | Clinical application of transcriptional activators of bile salt transporters |
| Q64044703 | Clinical guidelines for primary sclerosing cholangitis 2017 |
| Q36752084 | Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q49567497 | Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment. |
| Q49650135 | Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner. |
| Q93046523 | Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials |
| Q47615113 | Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. |
| Q38744215 | Emerging drugs for the treatment of Primary Biliary Cholangitis |
| Q90722936 | Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities |
| Q35889448 | Fibrates and cholestasis |
| Q42649890 | Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come |
| Q33721771 | Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial |
| Q46135644 | From pathogenesis to novel therapies in the treatment of primary biliary cholangitis |
| Q56429943 | Guidelines for the management of primary biliary cirrhosis |
| Q64940064 | Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model. |
| Q58702534 | Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis |
| Q52801689 | In vitro cytogenetic toxicity of bezafibrate in human peripheral blood lymphocytes. |
| Q38711012 | Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate. |
| Q53098304 | Investigational drugs in phase II clinical trials for primary biliary cholangitis. |
| Q38620686 | It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology |
| Q34043010 | Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation |
| Q38774857 | Management of cholestatic disease in 2017. |
| Q38266172 | New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition |
| Q46182874 | New therapeutics in primary biliary cirrhosis: will there ever be light? |
| Q38261577 | New therapies for primary biliary cirrhosis |
| Q28066233 | Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? |
| Q36786270 | Nuclear receptors as drug targets in cholestatic liver diseases |
| Q38074991 | Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver |
| Q34053116 | PPARα: A Master Regulator of Bilirubin Homeostasis |
| Q104288323 | Primary biliary cholangitis |
| Q46078221 | Primary biliary cholangitis: a comprehensive overview |
| Q54390436 | Primary biliary cholangitis: new treatments for an old disease. |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q26853649 | Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy |
| Q37072380 | Proposed therapies in primary biliary cholangitis |
| Q26748537 | Recent advances in understanding and managing cholestasis |
| Q38174167 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q26778511 | Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis |
| Q35942610 | The Cholangiopathies |
| Q90013058 | Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans |
| Q48496557 | Tissue distribution and ontogeny of multidrug resistance protein 2, a phosphatidylcholine translocator, in rats |
| Q39314534 | Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. |
| Q64991757 | Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? |
| Q55190939 | Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. |
| Q37590885 | Upregulation of PDZK1 by Calculus Bovis Sativus May Play an Important Role in Restoring Biliary Transport Function in Intrahepatic Cholestasis |
Search more.